BackgroundDurvalumab consolidation after concurrent chemoradiotherapy (cCRT) is the standard-of-care for unresectable stage III non-small cell lung cancer (NSCLC) without actionable driver mutations. However, pneumonitis remains a dose-limiting toxicity that often precludes or interrupts immunotherapy. Conventional predictors based on lung dosimetry alone exhibit limited individual-level discrimination. We investigated whether the thymus, long considered vestigial in adults, influences post-treatment immune recovery and…
Thymus Composition Predicts Pneumonitis Risk in Lung Cancer Therapy
medRxiv Oncology | | Chaunzwa, T. L., Krishnan, G., Amoako-Boadu, K., Book, A. J., Miller, D. G., Garomsa, B., Meng, Y. J., Yang, E., Chidi, A., Ma, J., Chaft, J. E., Shaverdian, N., Gomez, D. R.
Topics: lung-cancer, blood-cancer, immunotherapy, chemotherapy, radiation